Date:1/20/2012

g timely approval of the Preterm Birth NDA by the FDA; the timing and level of success of a future product launch, if any; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations, including Medicaid; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; the ability to obtain and enforce patents and other intellectual property rights; the impact of competitive products and pricing; the timely and successful negotiation of partnerships or other transactions; the strength of the United States dollar relative to international currencies; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's and Watson's reports filed with the SEC, including, but not limited to, their respective Annual Reports on Form 10-K for the year ended December 31, 2010 and Quarterly Reports on Form 10-Q for the period ended September 30, 2011. Neither Columbia nor Watson undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

CRINONE® is a registered trademark of Watson Pharmaceuticals, Inc.

ContactsFor Columbia Laboratories, Inc.

For Watson Pharmaceuticals, Inc. Investors

InvestorsLawrence A. Gyenes

Patty EisenhaurSVP, Chief Financial Officer & Treasurer

VP, Investor Relations and Corp. Comm. Columbia Laboratories, Inc.

(862) 261-8141(973) 486-8860

 --or--

MediaSeth Lewis

Charlie MayrVP, The Trout Group LLC

SVP, Corporate A
'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Sutro Announces Newly Formed Scientific Advisory Board
2. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
3. DiaTech Life Sciences Announces Medical Advisory Board
4. GenturaDx Announces Formation of Scientific Advisory Board
5. Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board
6. Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board
7. CBI Announces 3rd Effective Preparation for FDA Advisory Committees
8. NuMe Health Advances its Cobiotics™ Technology With Addition of Scientific Advisory Board and Filing of Patent Application for First Product
9. Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
10. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
11. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States